Bolton LP’s Supernus Pharmaceuticals SUPN Stock Holding History

Bolton LP’s Portfolio SUPN Stock Details SUPN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2014 Q2	–	Sell	-50,000	Closed	-$447K	–	159
2014 Q1	$447K	Buy	+50,000	New	+$460K	0.1%	109

Other funds holding SUPN

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

Abingworth London, United Kingdom $307M AUM 93.47% 1-Year Est. Return

T. Rowe Price Associates

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Michael R. Murphy $255M AUM 0.87% 1-Year Est. Return

Ardsley Advisory Partners Stamford, Connecticut $960M AUM 207.76% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return

Orchard Hill Capital Management New York $22.6M AUM 3.52% 1-Year Est. Return

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Northpointe Capital Bloomfield Hills, Michigan $258M AUM 1.97% 1-Year Est. Return

Bolton LP's SUPN Position: Q2 2014 in Review

Bolton LP sold out of Supernus Pharmaceuticals (SUPN) in Q2 2014, closing a stake of 50,000 shares — an estimated $447K sold.

Bolton LP first reported a position in SUPN in Q1 2014 and held it in 1 quarter. The position peaked at $447K in Q1 2014. 88 funds tracked by Wall St. Rank hold SUPN as of Q2 2014.

Bolton LP reported no remaining Supernus Pharmaceuticals position as of Q2 2014 after selling out during the quarter.
Bolton LP sold 50,000 Supernus Pharmaceuticals shares in Q2 2014, an estimated $447K.
Bolton LP first reported a position in Supernus Pharmaceuticals in Q1 2014 and held it in 1 quarter.
Bolton LP's Supernus Pharmaceuticals position peaked at $447K in Q1 2014.
88 funds tracked by Wall St. Rank held Supernus Pharmaceuticals as of Q2 2014.

Based on Bolton LP's 13F filing for Q2 2014, filed 14 Aug 2014.